UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of 

the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): February 19, 2016 (February 16, 2016) 

REGENERON PHARMACEUTICALS, INC. 

(Exact name of registrant as specified in its charter) 

New York 

(State or other jurisdiction of incorporation) 

 [DATA_TABLE_REMOVED]  

Registrant’s telephone number, including area code: (914) 847-7000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

On February 16, 2016, Douglas S. McCorkle notified Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) of his intention to retire from his position as Vice President, Controller and Assistant Treasurer of the Company in early 2017. Mr. McCorkle has served as Regeneron’s principal accounting officer since 1998. 

2 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

3